Earlier this year, Summit Therapeutics and Akeso unveiled new data on their PD-1/VEGF-A bispecific drug, ivonescimab, showing ...

A significant portion of patients in the Jemperli group continued treatment, with 36% still receiving therapy compared to 21% ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Combination Dose Escalation Tumor Response: Encouraging preliminary signs of anti-tumor activity were observed with MDNA11 in combination with KEYTRUDA in dose escalation cohorts 1 and 2. Among 5 ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...